Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kieran F Docherty

Showing results (31-40 of 174) with videos related to

Pageof 18
Sort By:
JACC. Heart Failure|October 2, 2020
Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HFKieran F Docherty, Muthiah Vaduganathan, Scott D Solomon, et al.
Acta Cardiologica|January 17, 2019
Chest pain with less than 20% change in high sensitivity troponin T - a low risk cohort?Robin A P Weir, Joanna Osmanska, Kieran F Docherty, et al.
European Heart Journal|January 4, 2020
The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in contextJohn J V McMurray, Scott D Solomon, Kieran F Docherty, et al.
Atherosclerosis|November 13, 2012
Statin treatment of children with familial hypercholesterolemia--trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus?Alpo Vuorio, Kieran F Docherty, Steve E Humphries, et al.
European Heart Journal|October 16, 2016
How robust are clinical trials in heart failure?Kieran F Docherty, Ross T Campbell, Pardeep S Jhund, et al.
Circulation|August 18, 2025
Response by Docherty et al to Letter Regarding Article, "Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial"Kieran F Docherty, Alasdair D Henderson, Pardeep S Jhund, et al.
JAMA Neurology|December 18, 2023
Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers: A Secondary Analysis of a Randomized Clinical TrialWagner S Brum, Kieran F Docherty, Nicholas J Ashton, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|November 9, 2024
Subcutaneous furosemide in heart failure: a systematic reviewJoanna Osmanska, Mark C Petrie, Kieran F Docherty, et al.
Nature Medicine|October 9, 2023
Recent successes in heart failure treatmentCarolyn S P Lam, Kieran F Docherty, Jennifer E Ho, et al.
Journal of the American College of Cardiology|September 1, 2024
Why Have We Not Been Able to Demonstrate Reduced Mortality in Patients With HFmrEF/HFpEF?Toru Kondo, Alasdair D Henderson, Kieran F Docherty, et al.
Pageof 18

Showing results (31-40 of 174) with videos related to

Sort By:
Pageof 18
JACC. Heart Failure|October 2, 2020
Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HFKieran F Docherty, Muthiah Vaduganathan, Scott D Solomon, et al.
Acta Cardiologica|January 17, 2019
Chest pain with less than 20% change in high sensitivity troponin T - a low risk cohort?Robin A P Weir, Joanna Osmanska, Kieran F Docherty, et al.
European Heart Journal|January 4, 2020
The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in contextJohn J V McMurray, Scott D Solomon, Kieran F Docherty, et al.
Atherosclerosis|November 13, 2012
Statin treatment of children with familial hypercholesterolemia--trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus?Alpo Vuorio, Kieran F Docherty, Steve E Humphries, et al.
European Heart Journal|October 16, 2016
How robust are clinical trials in heart failure?Kieran F Docherty, Ross T Campbell, Pardeep S Jhund, et al.
Circulation|August 18, 2025
Response by Docherty et al to Letter Regarding Article, "Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial"Kieran F Docherty, Alasdair D Henderson, Pardeep S Jhund, et al.
JAMA Neurology|December 18, 2023
Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers: A Secondary Analysis of a Randomized Clinical TrialWagner S Brum, Kieran F Docherty, Nicholas J Ashton, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|November 9, 2024
Subcutaneous furosemide in heart failure: a systematic reviewJoanna Osmanska, Mark C Petrie, Kieran F Docherty, et al.
Nature Medicine|October 9, 2023
Recent successes in heart failure treatmentCarolyn S P Lam, Kieran F Docherty, Jennifer E Ho, et al.
Journal of the American College of Cardiology|September 1, 2024
Why Have We Not Been Able to Demonstrate Reduced Mortality in Patients With HFmrEF/HFpEF?Toru Kondo, Alasdair D Henderson, Kieran F Docherty, et al.
Pageof 18